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with generalized estimating equations were used to estimate the
odds of being persistent for each LMD class relative to statins
while controlling for patient, plan, and prescription characteris-
tics. RESULTS: The overall proportion of patients persistent to
therapy in the 1 year after therapy initiation was 11% for BAS
(N = 9853), 25% for ER niacin (N = 9404), 32% for ﬁbrates (N
= 21,004), 39% for statins (N = 105,178), and 44% for eze-
timibe (N = 974). The proportion of patients who were persis-
tent with ER niacin therapy declined from 44% to 30%, 27%,
and 24% over the ﬁrst four quarters after therapy initiation. Sim-
ilarly, mean PDC for niacin was 68% in Q1, 43% in Q2, 36%
in Q3, and 32% in Q4 of the 1 year after therapy initiation.
Excepting ezetimibe, multivariate analyses conﬁrmed signiﬁ-
cantly lower odds of persistence on all LMD classes relative to
statins (p < 0.001). CONCLUSION: Excepting BAS, we found
that ER niacin had the lowest persistence among all LMD
classes. Since long-term treatment is generally necessary in
persons with dyslipidemia, suboptimal persistence may affect the
overall success of LMD therapy.
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OBJECTIVE: To evaluate the effect of a new program that
allowed patients to ﬁll 90-day prescriptions in retail pharmacies.
METHODS: The research is a case-control natural experiment.
A total of 38,852 patients in the treatment cohort received drug
beneﬁt through a managed care organization that initiated a 
90-day supply retail option in January 1, 2005. Patients were
evaluated if they used agents to treat diabetes, dyslipidemia, or
hypertension and were continuously eligible for beneﬁt for 18
months—9 months pre- and post-January 1, 2005. The control
cohort comprised 49,738 patients who were insured in the same
managed care organization, and used the same drugs and were
followed for the same length of time the year before and after
January 1, 2004. Treatment and control patients were matched
on a number of dimensions—including demographic character-
istics, copays, and baseline drug consumption—using the
weighted sum of absolute case-control differences. The effect of
the new 90-day retail program was then evaluated with the
matched sample using the difference-in-differences estimator.
Two outcomes were evaluated: the number of prescription in the
above therapeutic classes and the duration of supply. RESULTS:
The introduction of 90-day dispensing at retail allowed patients
to reduce the number of prescription they ﬁlled by an average of
1.2 for diabetes, 2.2 for antilipidemics, and 4.0 for antihyper-
tensives. Despite this reduction, actual total drug supply
increased as the average length of supply per prescription
increased. Total supply increased by 4.3 days for antihyperten-
sives, 11.5 days for antilipidemics, and by 75.3 days for diabetes.
CONCLUSION: Reactions to the introduction of a new retail
dispensing option demonstrate that dispensing ﬂexibility is valu-
able to the patients and can lead to improvement in compliance,
presumably because reﬁlling a prescription every 30 days can be
burdensome.
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OBJECTIVES: We investigated the “real world” effectiveness of
statin therapy, focusing on the effect of dose and early treatment
discontinuation on the risk for acute myocardial infarction
(AMI). METHODS: Data were obtained from the PHARMO
Record Linkage System including among others linked drug-dis-
pensing records and hospital records for over two million indi-
viduals of the Netherlands. New users of statins in the period
January 1 1991 until December 31 2004, °Y´18 years of age were
included in the study cohort. Exposure to statins, both in terms
of persistence and dose, was determined over the ﬁrst two treat-
ment years. To determine the risk for AMI, patients were fol-
lowed from this two-year time point until the ﬁrst hospital
admission for AMI, death, or end of the study period (Decem-
ber 31, 2004), whichever was earliest. Patients were classiﬁed
into two groups according to their risk of cardiovascular disease
at the start of outcome follow-up. RESULTS: The study cohort
included 46,332 low-risk statin users (78%) and 12,762 high-
risk statin users (22%). 31,557 patients (53%) discontinued
statin use within two years. 20,883 patients (35%) were persis-
tent statin users with an average equipotent dose °Y´4. A 40%
reduction in risk of AMI with two-year persistent statin use was
observed in low- and high-risk users. The protective effect of
statin use increased with a higher equipotent dose; a 25% reduc-
tion in risk of AMI with an average equipotent dose °Ü3 and a
60% risk reduction with an average equipotent dose °Y´4. CON-
CLUSION: The results show that statins are suboptimally dosed
in real life and used too short for having the maximum beneﬁt
in terms of preventing AMI. Our ﬁndings corroborate ﬁndings
from clinical trials insofar that the longer patients are treated 
and the higher the dose, the more successful the prevention of
AMI.
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OBJECTIVES: While managed care data can be used to assess
medication compliance and persistence, these databases gener-
ally do not permit observation of long-term outcomes. We there-
fore applied modeling techniques to explore the impacts of
compliance and persistence with hypertension therapy on long-
term cardiovascular outcomes among managed care hyperten-
sion patients. METHODS: We analyzed 12-month blood
pressure (BP) and compliance/persistence using data for hyper-
tension patients receiving valsartan therapy from the Geisinger
Clinic, a U.S. regional healthcare network. Long-term cardio-
vascular outcomes (myocardial infarction, stroke, coronary
artery bypass, angioplasty, and cardiovascular death) were based
on algorithms from the Physicians’ Health Study (13 years
follow-up) and Women’s Health Study (7 years) as presented by
Glynn et al. (2002). No signiﬁcant differences were observed
